R Palui1, J Sahoo2, S Kamalanathan1, S S Kar3, S Selvarajan4, H Durgia1. 1. Department of Endocrinology, JIPMER, Fourth Floor, Superspecialty Block, Puducherry, 605006, India. 2. Department of Endocrinology, JIPMER, Fourth Floor, Superspecialty Block, Puducherry, 605006, India. jppgi@yahoo.com. 3. Department of Preventive and Social Medicine, JIPMER, Puducherry, India. 4. Department of Clinical Pharmacology, JIPMER, Puducherry, India.
Abstract
CONTEXT: The primary treatment of choice for Cushing's disease (CD) is the removal of the pituitary adenoma by transsphenoidal surgery (TSS). The surgical failure is seen in up to 75% of cases depending on the experience of the surgeon in different studies. Medical therapy is one of the options for the treatment of recurrent or persistent CD. METHODOLOGY: The primary outcome of this meta-analysis was to find the proportion of patients achieving normalisation of 24-h urinary free cortisol (remission of CD) following cabergoline monotherapy. Literature search was conducted in January 2018 in PubMed/MEDLINE database from its date of inception to 31st December 2017. The search strategy used was "[(cushing) OR Cushing's] AND cabergoline". Individual participant data were extracted from the included studies and risk of bias was analysed by review checklist proposed by MOOSE. RESULTS: The individual participant data of 124 patients from six observational studies were included in this meta-analysis. 92 patients (74.2%) had past pituitary surgery. The proportion of patients achieving remission of Cushing’s disease (CD) with cabergoline monotherapy was 34% (95% confidence interval 0.26–0.43; P = 0.001) [corrected]. The previous surgery [odds ratio (OR) 28.4], duration of cabergoline monotherapy (OR 1.31) and maximum cabergoline dose (OR 0.19) were predictors for remission of CD. Mild and severe side effects were reported in 37.3% and 5.6% of patients, respectively, during cabergoline monotherapy. CONCLUSIONS: This meta-analysis shows that cabergoline monotherapy is a reasonable alternative for subjects with persistent or recurrent CD after TSS. It can also be used in CD patients either as a bridge therapy while waiting for surgery or in those unwilling for surgery or have contraindication to it.
CONTEXT: The primary treatment of choice for Cushing's disease (CD) is the removal of the pituitary adenoma by transsphenoidal surgery (TSS). The surgical failure is seen in up to 75% of cases depending on the experience of the surgeon in different studies. Medical therapy is one of the options for the treatment of recurrent or persistent CD. METHODOLOGY: The primary outcome of this meta-analysis was to find the proportion of patients achieving normalisation of 24-h urinary free cortisol (remission of CD) following cabergoline monotherapy. Literature search was conducted in January 2018 in PubMed/MEDLINE database from its date of inception to 31st December 2017. The search strategy used was "[(cushing) OR Cushing's] AND cabergoline". Individual participant data were extracted from the included studies and risk of bias was analysed by review checklist proposed by MOOSE. RESULTS: The individual participant data of 124 patients from six observational studies were included in this meta-analysis. 92 patients (74.2%) had past pituitary surgery. The proportion of patients achieving remission of Cushing’s disease (CD) with cabergoline monotherapy was 34% (95% confidence interval 0.26–0.43; P = 0.001) [corrected]. The previous surgery [odds ratio (OR) 28.4], duration of cabergoline monotherapy (OR 1.31) and maximum cabergoline dose (OR 0.19) were predictors for remission of CD. Mild and severe side effects were reported in 37.3% and 5.6% of patients, respectively, during cabergoline monotherapy. CONCLUSIONS: This meta-analysis shows that cabergoline monotherapy is a reasonable alternative for subjects with persistent or recurrent CD after TSS. It can also be used in CD patients either as a bridge therapy while waiting for surgery or in those unwilling for surgery or have contraindication to it.
Authors: Richard A Feelders; Christiaan de Bruin; Alberto M Pereira; Johannes A Romijn; Romana T Netea-Maier; Ad R Hermus; Pierre M Zelissen; Ramona van Heerebeek; Frank H de Jong; Aart-Jan van der Lely; Wouter W de Herder; Leo J Hofland; Steven W Lamberts Journal: N Engl J Med Date: 2010-05-13 Impact factor: 91.245
Authors: Lesley A Stewart; Mike Clarke; Maroeska Rovers; Richard D Riley; Mark Simmonds; Gavin Stewart; Jayne F Tierney Journal: JAMA Date: 2015-04-28 Impact factor: 56.272
Authors: Rosario Pivonello; Maria Cristina De Martino; Paolo Cappabianca; Monica De Leo; Antongiulio Faggiano; Gaetano Lombardi; Leo J Hofland; Steven W J Lamberts; Annamaria Colao Journal: J Clin Endocrinol Metab Date: 2008-10-28 Impact factor: 5.958
Authors: Christiaan de Bruin; Alberto M Pereira; Richard A Feelders; Johannes A Romijn; Ferdinand Roelfsema; Diane M Sprij-Mooij; Maarten O van Aken; Aart-Jan van der Lelij; Wouter W de Herder; Steven W J Lamberts; Leo J Hofland Journal: J Clin Endocrinol Metab Date: 2009-01-13 Impact factor: 5.958
Authors: Rosario Pivonello; Maria Cristina De Martino; Monica De Leo; Gaetano Lombardi; Annamaria Colao Journal: Endocrinol Metab Clin North Am Date: 2008-03 Impact factor: 4.741
Authors: Kalyani Sridharan; Jayaprakash Sahoo; Rajan Palui; Milind Patil; Sadishkumar Kamalanathan; A S Ramesh; N S Kubera Journal: Pituitary Date: 2021-03-29 Impact factor: 4.107